China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory Authority (SAHPRA) has awarded conditional registration to the company’s COVID-19 vaccine CoronaVac. The approval permits the vaccine’s use in adults aged 18 and over, administered in two doses with a 14-28-day interval.
Approval Background
This conditional registration follows SAHPRA’s earlier emergency use approval issued in July 2021. Since that time, Sinovac has been providing updates on safety and pharmacovigilance reports as well as clinical trial progress to South African authorities. The approval marks a significant milestone in the global rollout of CoronaVac.
Global Impact
CoronaVac is now available in more than 60 countries and has been administered approximately 2.9 billion times worldwide. This widespread use underscores the vaccine’s role in global efforts to combat the COVID-19 pandemic.-Fineline Info & Tech
